Drug Trial Radar · NCT01225237
A Study to Evaluate Efficacy of Ramosetron on Diarrhea-predominant Irritable Bowel Syndrome (IBS) in Male Patients
Last checked: Nov 20, 2026Latest source record: Oct 15, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
296
Actual
Start
Oct 2010
Primary completion
Aug 2011
Study completion Aug 2011
Sponsor
- Lead sponsor
- Astellas Pharma IncAstellas (ALPMY)
- Sponsor type
- Industry
- First posted
- Oct 20, 2010
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- Male only, from 20 years, up to 64 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A study to verify the superiority of ramosetron hydrochloride (Irribow Tablets) to placebo for male patients with diarrhea-predominant irritable bowel syndrome (D-IBS) and to evaluate its safety.
Conditions
- Irritable Bowel Syndrome
Interventions
RamosetronDrug
oral
PlaceboDrug
oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Responder rate of stool form normalizationTime frame: For 4 weeks
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Hokkaido, Japan
Site not named
Kansai, Japan
Site not named
Kantou, Japan
Site not named
Kyusyu, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.